GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005109814 | Breast | IDC | regulation of binding | 57/1434 | 363/18723 | 1.59e-07 | 8.76e-06 | 57 |
GO:005109914 | Breast | IDC | positive regulation of binding | 30/1434 | 173/18723 | 1.96e-05 | 4.86e-04 | 30 |
GO:000164912 | Breast | IDC | osteoblast differentiation | 35/1434 | 229/18723 | 6.64e-05 | 1.35e-03 | 35 |
GO:006056212 | Breast | IDC | epithelial tube morphogenesis | 44/1434 | 325/18723 | 1.58e-04 | 2.73e-03 | 44 |
GO:000150311 | Breast | IDC | ossification | 50/1434 | 408/18723 | 6.51e-04 | 8.04e-03 | 50 |
GO:003514812 | Breast | IDC | tube formation | 23/1434 | 148/18723 | 8.79e-04 | 1.02e-02 | 23 |
GO:000183812 | Breast | IDC | embryonic epithelial tube formation | 19/1434 | 121/18723 | 2.10e-03 | 1.97e-02 | 19 |
GO:00721756 | Breast | IDC | epithelial tube formation | 19/1434 | 132/18723 | 5.63e-03 | 4.08e-02 | 19 |
GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
GO:00301117 | Cervix | CC | regulation of Wnt signaling pathway | 76/2311 | 328/18723 | 3.05e-08 | 2.08e-06 | 76 |
GO:005109810 | Cervix | CC | regulation of binding | 80/2311 | 363/18723 | 1.32e-07 | 6.42e-06 | 80 |
GO:00608287 | Cervix | CC | regulation of canonical Wnt signaling pathway | 58/2311 | 253/18723 | 1.83e-06 | 5.89e-05 | 58 |
GO:00600707 | Cervix | CC | canonical Wnt signaling pathway | 66/2311 | 303/18723 | 2.47e-06 | 7.35e-05 | 66 |
GO:005109910 | Cervix | CC | positive regulation of binding | 42/2311 | 173/18723 | 1.07e-05 | 2.33e-04 | 42 |
GO:00433939 | Cervix | CC | regulation of protein binding | 42/2311 | 196/18723 | 2.27e-04 | 2.55e-03 | 42 |
GO:00016497 | Cervix | CC | osteoblast differentiation | 47/2311 | 229/18723 | 2.88e-04 | 3.11e-03 | 47 |
GO:00320927 | Cervix | CC | positive regulation of protein binding | 21/2311 | 85/18723 | 1.27e-03 | 1.01e-02 | 21 |
GO:0045667 | Cervix | CC | regulation of osteoblast differentiation | 29/2311 | 132/18723 | 1.32e-03 | 1.05e-02 | 29 |
GO:00301784 | Cervix | CC | negative regulation of Wnt signaling pathway | 35/2311 | 170/18723 | 1.52e-03 | 1.17e-02 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HRC | SNV | Missense_Mutation | novel | c.751G>A | p.Asp251Asn | p.D251N | P23327 | protein_coding | tolerated(0.12) | possibly_damaging(0.685) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
HRC | SNV | Missense_Mutation | novel | c.1345N>C | p.Glu449Gln | p.E449Q | P23327 | protein_coding | tolerated(0.3) | benign(0.067) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
HRC | SNV | Missense_Mutation | | c.1431N>C | p.Leu477Phe | p.L477F | P23327 | protein_coding | tolerated(0.12) | benign(0.044) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HRC | SNV | Missense_Mutation | | c.1758N>G | p.Ile586Met | p.I586M | P23327 | protein_coding | deleterious(0) | possibly_damaging(0.854) | TCGA-AO-A1KR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
HRC | SNV | Missense_Mutation | novel | c.811N>T | p.His271Tyr | p.H271Y | P23327 | protein_coding | tolerated(0.06) | probably_damaging(0.982) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HRC | SNV | Missense_Mutation | rs766836022 | c.1951N>A | p.Glu651Lys | p.E651K | P23327 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
HRC | SNV | Missense_Mutation | novel | c.1600G>A | p.Glu534Lys | p.E534K | P23327 | protein_coding | deleterious(0) | possibly_damaging(0.587) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
HRC | SNV | Missense_Mutation | | c.68N>A | p.Pro23His | p.P23H | P23327 | protein_coding | deleterious(0) | possibly_damaging(0.543) | TCGA-E2-A158-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | arimidex | SD |
HRC | SNV | Missense_Mutation | novel | c.704G>C | p.Gly235Ala | p.G235A | P23327 | protein_coding | tolerated(0.51) | benign(0) | TCGA-C5-A1M6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
HRC | SNV | Missense_Mutation | rs563550433 | c.872G>A | p.Arg291His | p.R291H | P23327 | protein_coding | tolerated(1) | benign(0) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |